AI drug design races ahead while clinical trials become the bottleneck

MaxUnfried · x · 2026-11-22

furstfly argues AI's biggest impact is in drug design, shifting the bottleneck to labs and clinical trials: by the time one drug finishes Phase 1, a next candidate could be 50% better — and doubled efficacy needs roughly 4x fewer patients, speeding enrollment and early stops. Reposter adds many FDA complaints excuse weak therapies.

Original post →

More from AGI Musings

AGI Musings channel →